This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thalhammer, F.
Right arrow Articles by Ratheiser, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thalhammer, F.
Right arrow Articles by Ratheiser, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 1998, p. 2417-2420, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Single-Dose Pharmacokinetics of Meropenem during Continuous Venovenous Hemofiltration

Florian Thalhammer,1,* Peter Schenk,2 Heinz Burgmann,1 Ibrahim El Menyawi,1 Ursula M. Hollenstein,1 Alexander R. Rosenkranz,3 Gere Sunder-Plassmann,3 Stefan Breyer,1 and Klaus Ratheiser2

Department of Internal Medicine I, Division of Infectious Diseases,1 Department of Internal Medicine IV, Intensive Care Unit,2 and Department of Internal Medicine III, Division of Nephrology and Dialysis,3 University of Vienna, A-1090 Vienna, Austria

Received 13 January 1998/Returned for modification 26 April 1998/Accepted 15 June 1998

The pharmacokinetic properties of meropenem were investigated in nine critically ill patients treated by continuous venovenous hemofiltration (CVVH). All patients received one dose of 1 g of meropenem intravenously. High-flux polysulfone membranes were used as dialyzers. Meropenem levels were measured in plasma and ultrafiltrate by high-performance liquid chromatography. The total body clearance and elimination half-life were 143.7 ± 18.6 ml/min and 2.46 ± 0.41 h, respectively. The post- to prehemofiltration ratio of meropenem was 0.24 ± 0.06. Peak plasma drug concentrations measured 60 min postinfusion were 28.1 ± 2.7 µg/ml, and trough levels after 6 h of CVVH were 6.6 ± 1.5 µg/ml. The calculated total daily meropenem requirement in these patients with acute renal failure and undergoing CVVH was 2,482 ± 321 mg. Based on these data, we conclude that patients with severe infections who are undergoing CVVH can be treated effectively with 1 g of meropenem every 8 h.

* Corresponding author. Mailing address: Department of Internal Medicine I, Division of Infectious Diseases, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40 400-44 40. Fax: 49-89-66617-18696. E-mail: florian.thalhammer{at}akh-wien.ac.at.

Antimicrobial Agents and Chemotherapy, September 1998, p. 2417-2420, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Li, A. M. M. Y., Gomersall, C. D., Choi, G., Tian, Q., Joynt, G. M., Lipman, J. (2009). A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?. J Antimicrob Chemother 64: 929-937 [Abstract] [Full Text]  
  • Gattringer, R., Meyer, B., Heinz, G., Guttmann, C., Zeitlinger, M., Joukhadar, C., Dittrich, P., Thalhammer, F. (2006). Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother 58: 367-371 [Abstract] [Full Text]  
  • Isla, A., Maynar, J., Sanchez-Izquierdo, J. A., Gascon, A. R., Arzuaga, A., Corral, E., Pedraz, J. L. (2005). Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients. J Clin Pharmacol 45: 1294-1304 [Abstract] [Full Text]  
  • Krueger, W. A., Bulitta, J., Kinzig-Schippers, M., Landersdorfer, C., Holzgrabe, U., Naber, K. G., Drusano, G. L., Sorgel, F. (2005). Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers. Antimicrob. Agents Chemother. 49: 1881-1889 [Abstract] [Full Text]  
  • Robatel, C., Decosterd, L. A., Biollaz, J., Eckert, P., Schaller, M. D., Buclin, T. (2003). Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. J Clin Pharmacol 43: 1329-1340 [Abstract] [Full Text]  
  • Traunmuller, F., Schenk, P., Mittermeyer, C., Thalhammer-Scherrer, R., Ratheiser, K., Thalhammer, F. (2002). Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 49: 129-134 [Abstract] [Full Text]  
  • Traunmuller, F., Thalhammer-Scherrer, R., Locker, G. J., Losert, H., Schmid, R., Staudinger, T., Thalhammer, F. (2001). Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother 47: 229-231 [Abstract] [Full Text]  
  • Valtonen, M., Tiula, E., Backman, J. T., Neuvonen, P. J. (2000). Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 45: 701-704 [Abstract] [Full Text]  
  • Thalhammer, F., Traunmuller, F., El Menyawi, I., Frass, M., Hollenstein, U. M., Locker, G. J., Stoiser, B., Staudinger, T., Thalhammer-Scherrer, R., Burgmann, H. (1999). Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43: 523-527 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»